These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 17678460)

  • 41. Heparin-Induced Thrombocytopenia in Infants after Heart Surgery.
    Abdillah JN; Hu Q; Chen X; Chen X; Zhou W; Luo W; Huang L
    Thorac Cardiovasc Surg; 2019 Jan; 67(1):21-27. PubMed ID: 29605959
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Thrombocytopenia following heparin flush.
    McNulty I; Katz E; Kim KY
    Prog Cardiovasc Nurs; 2005; 20(4):143-7. PubMed ID: 16276136
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Argatroban anticoagulation in patients with a history of heparin-induced thrombocytopenia.
    Matthai WH; Hursting MJ; Lewis BE; Kelton JG
    Thromb Res; 2005; 116(2):121-6. PubMed ID: 15907526
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Apparent argatroban resistance in a patient with elevated factor VIII levels.
    Kennedy DM; Alaniz C
    Ann Pharmacother; 2013; 47(7-8):e29. PubMed ID: 23737512
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Argatroban dosing of patients with heparin-induced thrombocytopenia and an elevated aPTT due to antiphospholipid antibody syndrome.
    Pendleton R; Wheeler MM; Rodgers GM
    Ann Pharmacother; 2006 May; 40(5):972-6. PubMed ID: 16569813
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Argatroban and lepirudin requirements in a 6-year-old patient with heparin-induced thrombocytopenia.
    John TE; Hallisey RK
    Pharmacotherapy; 2005 Oct; 25(10):1383-8. PubMed ID: 16185183
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Argatroban anticoagulation for heparin induced thrombocytopenia in patients with ventricular assist devices.
    Pappalardo F; Scandroglio AM; Potapov E; Stepanenko A; Maj G; Krabatsch T; Zangrillo A; Koster A; Hetzer R
    Minerva Anestesiol; 2012 Mar; 78(3):330-5. PubMed ID: 22357371
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A comparison of direct thrombin inhibitors in the treatment of Heparin-Induced Thrombocytopenia: a single institution experience.
    Curzio KM; Cheng-Lai A; Kheyfets V; Sinnet M; Billett HH
    J Thromb Thrombolysis; 2009 Aug; 28(2):117-23. PubMed ID: 18827975
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prolonged anticoagulation after discontinuation of argatroban and warfarin therapy in an obese patient with heparin-induced thrombocytopenia.
    Shapiro NL; Durr EA; Krueger CD
    Pharmacotherapy; 2006 Dec; 26(12):1806-10. PubMed ID: 17125442
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Antithrombotic drugs for the treatment of heparin-induced thrombocytopenia.
    Jeske WP; Walenga JM
    Curr Opin Investig Drugs; 2002 Aug; 3(8):1171-80. PubMed ID: 12211410
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Argatroban anticoagulation in critically ill patients.
    Beiderlinden M; Treschan TA; Görlinger K; Peters J
    Ann Pharmacother; 2007 May; 41(5):749-54. PubMed ID: 17440009
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Heparin-induced thrombocytopenia: when a low platelet count is a mandate for anticoagulation.
    Ortel TL
    Hematology Am Soc Hematol Educ Program; 2009; ():225-32. PubMed ID: 20008202
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy and safety of argatroban in patients with heparin induced thrombocytopenia undergoing endovascular intervention for peripheral arterial disease.
    Baron SJ; Yeh RW; Cruz-Gonzalez I; Healy JL; Pomerantsev E; Garasic J; Drachman D; Rosenfield K; Jang IK
    Catheter Cardiovasc Interv; 2008 Jul; 72(1):116-20. PubMed ID: 18546237
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Argatroban in the management of heparin-induced thrombocytopenia.
    Babuin L; Pengo V
    Vasc Health Risk Manag; 2010 Sep; 6():813-9. PubMed ID: 20859550
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Argatroban: a review of its use in the management of heparin-induced thrombocytopenia.
    Dhillon S
    Am J Cardiovasc Drugs; 2009; 9(4):261-82. PubMed ID: 19655821
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Argatroban in HIT type II and acute coronary syndrome.
    Lewis BE; Walenga JM
    Pathophysiol Haemost Thromb; 2002; 32 Suppl 3():46-55. PubMed ID: 12811012
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects of critical illness and organ failure on therapeutic argatroban dosage requirements in patients with suspected or confirmed heparin-induced thrombocytopenia.
    Keegan SP; Gallagher EM; Ernst NE; Young EJ; Mueller EW
    Ann Pharmacother; 2009 Jan; 43(1):19-27. PubMed ID: 19116377
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Treatment options for heparin-induced thrombocytopenia.
    Greinacher A
    Am J Health Syst Pharm; 2003 Oct; 60 Suppl 5():S12-8. PubMed ID: 14593978
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Intravenous warfarin and heparin-induced thrombocytopenia: making the diagnosis, management, modern monitoring, and multidisciplinary care.
    Burger CF; Schlesinger JJ
    Ann Pharmacother; 2014 Feb; 48(2):286-91. PubMed ID: 24259642
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Alternative monitoring of argatroban using plasma-diluted thrombin time.
    Wanat MA; Hart SR; Putney D; Liebl MG; Chandler W
    Ann Pharmacother; 2013 Apr; 47(4):e18. PubMed ID: 23482736
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.